Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012 Aug; 71(8):1343-9.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.